ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Abstract P2-16-10: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer: Preliminary Results of an Ongoing Phase 1 Study
Mapping Intimacies
◽
10.1158/0008-5472.sabcs10-p2-16-10
◽
2010
◽
Cited By ~ 1
Author(s):
EL Mayer
◽
M Scheulen
◽
J Beckman
◽
H Richly
◽
A Poli
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase 1
◽
Metastatic Breast
◽
Weekly Paclitaxel
◽
Phase 1 Study
◽
Preliminary Results
◽
Ongoing Phase
Download Full-text
Related Documents
Cited By
References
Phase II study of weekly paclitaxel for docetaxel-resistant or -inapplicable metastatic breast cancer: Preliminary results
European Journal of Cancer
◽
10.1016/s0959-8049(02)80221-0
◽
2002
◽
Vol 38
(11)
◽
pp. S73
Author(s):
T Ajhara
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase Ii
◽
Phase Ii Study
◽
Metastatic Breast
◽
Weekly Paclitaxel
◽
Preliminary Results
Download Full-text
Abstract OT3-02-14: A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398)
10.1158/1538-7445.sabcs15-ot3-02-14
◽
2016
◽
Author(s):
JC Sachdev
◽
RK Ramanathan
◽
N Raghunand
◽
C Anders
◽
P Munster
◽
...
Keyword(s):
Breast Cancer
◽
Magnetic Resonance Imaging
◽
Metastatic Breast Cancer
◽
Phase 1
◽
Metastatic Breast
◽
Response To Treatment
◽
Resonance Imaging
◽
Phase 1 Study
◽
Potential Biomarker
◽
Nanoliposomal Irinotecan
Download Full-text
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
10.1158/1538-7445.sabcs17-pd3-14
◽
2018
◽
Cited By ~ 2
Author(s):
S Modi
◽
L Pusztai
◽
A Forero
◽
M Mita
◽
KD Miller
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Triple Negative
◽
Phase 1
◽
Metastatic Breast
◽
Antibody Drug Conjugate
◽
Phase 1 Study
◽
Drug Conjugate
◽
Heavily Pretreated
◽
Antibody Drug
Download Full-text
Abstract P4-15-09: Phase 1 study of trastuzumab emtansine in HER2-positive metastatic breast cancer patients with normal or reduced hepatic function
10.1158/1538-7445.sabcs14-p4-15-09
◽
2015
◽
Cited By ~ 1
Author(s):
Chunze Li
◽
Priya Agarwal
◽
Susan Dent
◽
Anthony Goncalves
◽
Joo-Hee Yi
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Cancer Patients
◽
Phase 1
◽
Metastatic Breast
◽
Hepatic Function
◽
Trastuzumab Emtansine
◽
Breast Cancer Patients
◽
Her2 Positive
◽
Phase 1 Study
Download Full-text
Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
10.1158/1538-7445.sabcs16-p6-12-04
◽
2017
◽
Cited By ~ 1
Author(s):
A Forero-Torres
◽
S Modi
◽
J Specht
◽
K Miller
◽
A Weise
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase 1
◽
Metastatic Breast
◽
Antibody Drug Conjugate
◽
Phase 1 Study
◽
Drug Conjugate
◽
Heavily Pretreated
◽
Antibody Drug
Download Full-text
Phase 1 study of triweekly nab-paclitaxel combined with S-1 in patients with HER2 negative metastatic breast cancer.
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.e12510
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. e12510-e12510
Author(s):
Katsuhiko Nakatsukasa
◽
Tetsuya Taguchi
◽
Kouichi Sakaguchi
◽
Yoshihumi Hujita
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase 1
◽
Metastatic Breast
◽
Phase 1 Study
Download Full-text
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer
Clinical Breast Cancer
◽
10.1016/j.clbc.2021.08.003
◽
2021
◽
Author(s):
Patricia LoRusso
◽
Erika Hamilton
◽
Cynthia Ma
◽
Neelima Vidula
◽
Rebecca G. Bagley
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Androgen Receptor
◽
Phase 1
◽
Metastatic Breast
◽
Selective Androgen Receptor Modulator
◽
Phase 1 Study
◽
Receptor Modulator
Download Full-text
Abstract P4-01-12: Circulating tumor cells (CTC) and endothelial cells (CEC) changes in HER2 negative metastatic breast cancer (MBC) patients treated with first line weekly paclitaxel and bevacizumab: Preliminary results of a prospective cohort from the French Breast Cancer
10.1158/1538-7445.sabcs14-p4-01-12
◽
2015
◽
Author(s):
Jean-Yves Pierga
◽
Isabelle Vaucher
◽
Maya Gutierrez
◽
Olivier Tredan
◽
Séverine Guiu
◽
...
Keyword(s):
Breast Cancer
◽
Endothelial Cells
◽
Metastatic Breast Cancer
◽
Tumor Cells
◽
Circulating Tumor Cells
◽
Prospective Cohort
◽
Metastatic Breast
◽
Weekly Paclitaxel
◽
First Line
◽
Preliminary Results
Download Full-text
Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.
Journal of Clinical Oncology
◽
10.1200/jco.2018.36.15_suppl.tps1108
◽
2018
◽
Vol 36
(15_suppl)
◽
pp. TPS1108-TPS1108
◽
Cited By ~ 1
Author(s):
Ruth O'Regan
◽
Randolph Hurley
◽
Jasgit C. Sachdev
◽
Debra A. Tonetti
◽
Gregory R. Thatcher
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Endocrine Therapy
◽
Phase 1
◽
Metastatic Breast
◽
Phase 1 Study
Download Full-text
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer
Cancer
◽
10.1002/cncr.26571
◽
2011
◽
Vol 118
(9)
◽
pp. 2378-2384
◽
Cited By ~ 16
Author(s):
Stacy Moulder
◽
Gregory Gladish
◽
Joe Ensor
◽
Ana Maria Gonzalez-Angulo
◽
Massimo Cristofanilli
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase 1
◽
Metastatic Breast
◽
Phase 1 Study
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close